Jul 20, 2021
Brii Biosciences Initiates Phase 2 Clinical Trial in China for Neutralizing Antibodies, BRII-196 and BRII-198, in SARS-CoV-2
Jul 13, 2021
Brii Biosciences Limited Successfully Listed on Main Board of Hong Kong Stock Exchange
